Ophthalmology
Volume 109, Issue 5 , Pages 862-868, May 2002

Limbal stem cell transplantation in chronic inflammatory eye disease

Historical Image

  • C.Michael Samson, MD

      Affiliations

    • Ocular Immunology and Uveitis Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
    • ,
  • Constance Nduaguba, MD

      Affiliations

    • Department of Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, USA
    • ,
  • Stefanos Baltatzis, MD

      Affiliations

    • Ocular Immunology and Uveitis Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
    • ,
  • C.Stephen Foster, MD

      Affiliations

    • Ocular Immunology and Uveitis Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
    • Corresponding Author InformationReprint requests to C. Stephen Foster, MD, Ocular Immunology and Uveitis Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114 USA

Received 7 June 2001; accepted 28 August 2001.

Manuscript no. 210386.

Abstract 

Objective

The goal of this study was to describe the outcome of limbal stem cell transplantation (LSCT) in patients with severe ocular surface disease caused by underlying chronic inflammatory eye disease.

Design

Retrospective noncomparative case series.

Participants

Nine patients with limbal stem cell deficiency caused by an underlying ocular inflammatory disease who underwent LSCT.

Methods

The authors reviewed the records of 11 eyes of 9 patients with immunologically mediated ocular surface disease that underwent LSCT.

Main outcome measures

The main outcome measures were reepithelialization of the corneal surface, restoration of corneal surface, and improvement in visual acuity.

Results

A total of 11 eyes underwent either autologous (n = 1) or HLA-matched living related donor (n = 10) LSCT for ocular surface disease secondary to inflammatory disease. Reepithelialization of the corneal surface in the immediate postoperative period occurred in 10 eyes (91%) within an average of 10 days (range, 3–21 days). Long-term restoration of the corneal surface was achieved in six (55%) eyes. Visual acuity improved in six eyes (55%). Reasons for poor outcomes included microbial infection, limbal stem cell graft rejection, and corneal ulceration. No donor eyes had complications.

Conclusions

Patients with underlying immunologically mediated diseases, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or ocular cicatricial pemphigoid, who undergo LSCT have lower success rates than do those patients with noninflammatory ocular surface diseases.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0161-6420(02)00994-6

Ophthalmology
Volume 109, Issue 5 , Pages 862-868, May 2002

Article Tools

* Image Usage & Resolution